Loading
A phase 3 trial of Mevrometostat, Enzalutamide in prostate cancer, run by Pfizer, now recruiting.
A Study to Learn How PF-06821497 (Mevrometostat) Works in Men With Metastatic Castration-resistant Prostate Cancer. is a phase 3 interventional study registered as NCT06629779 by Pfizer, with 900 participants planned, started 2024-10-22 and due to reach its primary completion in 2026-12-02. Interventions recorded: PF-06821497, Placebo, Enzalutamide. Conditions listed: Metastatic Castration-Resistant Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Mevrometostat, Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET).
Shares Mevrometostat, Enzalutamide, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Pfizer (incl. Seagen).
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), Metastatic castration-resistant prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Prostate cancer.
Shares Enzalutamide, Androgen deprivation & AR pathway inhibitors, Metastatic castration-resistant prostate cancer, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/